Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Nvidia earnings boost markets, NZ sharemarket closes up
Markets Market Close

Nvidia earnings boost markets, NZ sharemarket closes up

The S&P/NZX 50 Index closed up 0.84% or 112.502 points. 

Tom Raynel 20 Nov 2025
Jade Software to acquire Contec Group
Markets

Jade Software to acquire Contec Group

The acquisition adds Contec’s Madcap software to Jade’s portfolio.

John Anthony 20 Nov 2025
AFT forges ahead with China iron injectable deal
Markets

AFT forges ahead with China iron injectable deal

Oldest iron products in Aussie are booming, while new iron injectable gets China boost.

Meridian says hydro is key to energy security and affordability
Markets

Meridian says hydro is key to energy security and affordability

Meridian says it has learnt lessons from winter 2024.

Ian Llewellyn 20 Nov 2025